Drugs / QBW276
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02566044 | Sep 2017 → Apr 2018 | cystic fibrosis | Novartis Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QBW276 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02566044 ↗ |
| Route | Inhaled | “inhaled QBW276” NCT02566044 ↗ |